Ann Surg Treat Res.  2023 Dec;105(6):341-352. 10.4174/astr.2023.105.6.341.

Unveiling the profound advantages of total neoadjuvant therapy in rectal cancer: a trailblazing exploration

• Jung KU
• Kim HO
• Kim H
• Lee D
• Cheong C
• on the behalf of Korean Society of Coloproctology

• KMID: 2548778
• DOI: http://doi.org/10.4174/astr.2023.105.6.341

Abstract

The standard treatments for locally advanced rectal cancer typically involved neoadjuvant therapy with either short-course radiation or long-course chemoradiation, followed by radical surgery and adjuvant chemotherapy. While the advancement of surgical techniques and the adoption of multimodal therapy have greatly contributed to reducing local failure, there has been limited improvement in overall survival, primarily due to the stagnation in systemic failure. In response to this challenge, a new strategy known as total neoadjuvant therapy (TNT) has emerged, involving the administration of both fulldose chemotherapy and radiation before surgery. It has shown promise in reducing systemic failure, enhancing tumor regression, and improving treatment adherence, ushering in a new era in the standard treatment of locally advanced rectal cancer. This review aims to summarize the evolution of multimodal treatments for locally advanced rectal cancer, ultimately converging into the current TNT strategy, and provides an assessment of the benefits and limitations of TNT based on available evidence, serving as a foundation for selecting the best treatment option.

Keyword

Adenocarcinoma; Chemotherapy; Neoadjuvant therapy; Radiotherapy; Rectal neoplasms

Reference

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71:209–249. PMID: 33538338.

2. Lee TH, Choo JM, Kim JS, Shin SH, Kim JS, Baek SJ, et al. Characteristics and outcomes of colorectal cancer surgery by age in a tertiary center in Korea: a retrospective review. Ann Coloproctol. 2022; 38:244–252. PMID: 34735759.

3. Kim MH, Park S, Yi N, Kang B, Park IJ. Colorectal cancer mortality trends in the era of cancer survivorship in Korea: 2000-2020. Ann Coloproctol. 2022; 38:343–352. PMID: 36353833.

4. Araghi M, Soerjomataram I, Bardot A, Ferlay J, Cabasag CJ, Morrison DS, et al. Changes in colorectal cancer incidence in seven high-income countries: a population-based study. Lancet Gastroenterol Hepatol. 2019; 4:511–518. PMID: 31105047.

5. Park KS, Hong YK, Choi YJ, Kang JG. Clinicopathologic characteristics of early-onset colorectal cancer. Ann Coloproctol. 2022; 38:362–369. PMID: 35272449.

6. Stewart DB, Dietz DW. Total mesorectal excision: what are we doing? Clin Colon Rectal Surg. 2007; 20:190–202. PMID: 20011200.

7. Delibegovic S. Introduction to total mesorectal excision. Med Arch. 2017; 71:434–438. PMID: 29416206.

8. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009; 373:811–820. PMID: 19269519.

9. Li Y, Wang J, Ma X, Tan L, Yan Y, Xue C, et al. A review of neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Int J Biol Sci. 2016; 12:1022–1031. PMID: 27489505.

10. Sellés EG, Pieretti DG, Higuero PP, Del Portillo EG, Macías VM, Domínguez MM, et al. Total neoadjuvant therapy for locally advanced rectal cancer: a narrative review. Future Oncol. 2023; 19:1753–1768. PMID: 37650764.

11. Wong MC, Huang J, Lok V, Wang J, Fung F, Ding H, et al. Differences in incidence and mortality trends of colorectal cancer worldwide based on sex, age, and anatomic location. Clin Gastroenterol Hepatol. 2021; 19:955–966. PMID: 32088300.

12. Kasi A, Abbasi S, Handa S, Al-Rajabi R, Saeed A, Baranda J, et al. Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020; 3:e2030097. PMID: 33326026.

13. Zhu J, Lian J, Xu B, Pang X, Ji S, Zhao Y, et al. Neoadjuvant immunotherapy for colorectal cancer: right regimens, right patients, right directions? Front Immunol. 2023; 14:1120684. PMID: 36949951.

14. Mohiuddin M, Marks G. High dose preoperative irradiation for cancer of the rectum, 1976-1988. Int J Radiat Oncol Biol Phys. 1991; 20:37–43. PMID: 1993629.

15. Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med. 1985; 312:1465–1472. PMID: 2859523.

16. Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham DL, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988; 80:21–29. PMID: 3276900.

17. Krook JE, Loprinzi CL, Schaid DJ, Kardinal CG, Mailliard JA, Pfeifle DM, et al. Evaluation of the continuous infusion of etoposide plus cisplatin in metastatic breast cancer: a collaborative North Central Cancer Treatment Group/Mayo Clinic phase II study. Cancer. 1990; 65:418–421. PMID: 2297632.

18. Wolmark N, Fisher B. An analysis of survival and treatment failure following abdominoperineal and sphincter-saving resection in Dukes’ B and C rectal carcinoma: a report of the NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project. Ann Surg. 1986; 204:480–489. PMID: 3532972.

19. Thomas PR, Lindblad AS. Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience. Radiother Oncol. 1988; 13:245–252. PMID: 3064191.

20. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990; 264:1444–1450. PMID: 2202842.

21. Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006; 24:4620–4625. PMID: 17008704.

22. Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne PL, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012; 30:4558–4565. PMID: 23109696.

23. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011; 29:2773–2780. PMID: 21606427.

24. Schmoll HJ, Stein A, Van Cutsem E, Price T, Hofheinz RD, Nordlinger B, et al. Pre- and postoperative capecitabine without or with oxaliplatin in locally advanced rectal cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. J Clin Oncol. 2021; 39:17–29. PMID: 33001764.

25. Kalofonos HP, Bamias A, Koutras A, Papakostas P, Basdanis G, Samantas E, et al. A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study. Eur J Cancer. 2008; 44:1693–1700. PMID: 18639450.

26. Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol. 2012; 30:1620–1627. PMID: 22473163.

27. Nogué M, Salud A, Vicente P, Arriví A, Roca JM, Losa F, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist. 2011; 16:614–620. PMID: 21467148.

28. Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015; 16:979–989. PMID: 26189067.

29. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351:1731–1740. PMID: 15496622.

30. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006; 93:1215–1223. PMID: 16983741.

31. Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012; 30:3827–3833. PMID: 23008301.

32. Erlandsson J, Holm T, Pettersson D, Berglund Å, Cedermark B, Radu C, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017; 18:336–346. PMID: 28190762.

33. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012; 30:1926–1933. PMID: 22529255.

34. Elferink MA, van Steenbergen LN, Krijnen P, Lemmens VE, Rutten HJ, Marijnen CA, et al. Marked improvements in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989-2006. Eur J Cancer. 2010; 46:1421–1429. PMID: 20172711.

35. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006; 355:1114–1123. PMID: 16971718.

36. Sainato A, Cernusco Luna Nunzia V, Valentini V, De Paoli A, Maurizi ER, Lupattelli M, et al. No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol. 2014; 113:223–229. PMID: 25454175.

37. Glynne-Jones R, Counsell N, Quirke P, Mortensen N, Maraveyas A, Meadows HM, et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol. 2014; 25:1356–1362. PMID: 24718885.

38. Torky R, Alessa M, Kim HS, Sakr A, Zakarneh E, Sauri F, et al. Characteristics of patients presented with metastases during or after completion of chemoradiation therapy for locally advanced rectal cancer: a case series. Ann Coloproctol. 2021; 37:186–191. PMID: 32972094.

39. Bujko K, Wyrwicz L, Rutkowski A, Malinowska M, Pietrzak L, Kryński J, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016; 27:834–842. PMID: 26884592.

40. Ciseł B, Pietrzak L, Michalski W, Wyrwicz L, Rutkowski A, Kosakowska E, et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2019; 30:1298–1303. PMID: 31192355.

41. Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CA, Putter H, Kranenbarg EM, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22:29–42. PMID: 33301740.

42. Bahadoer RR, Hospers GA, Marijnen CA, Peeters KC, Putter H, Dijkstra EA, et al. Risk and location of distant metastases in patients with locally advanced rectal cancer after total neoadjuvant treatment or chemoradiotherapy in the RAPIDO trial. Eur J Cancer. 2023; 185:139–149. PMID: 36996624.

43. Garcia-Aguilar J, Chow OS, Smith DD, Marcet JE, Cataldo PA, Varma MG, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015; 16:957–966. PMID: 26187751.

44. Jin J, Tang Y, Hu C, Jiang LM, Jiang J, Li N, et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022; 40:1681–1692. PMID: 35263150.

45. Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol. 2010; 28:859–865. PMID: 20065174.

46. Fernandez-Martos C, Garcia-Albeniz X, Pericay C, Maurel J, Aparicio J, Montagut C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†. Ann Oncol. 2015; 26:1722–1728. PMID: 25957330.

47. Conroy T, Bosset JF, Etienne PL, Rio E, François É, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22:702–715. PMID: 33862000.

48. Fokas E, Allgäuer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, et al. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol. 2019; 37:3212–3222. PMID: 31150315.

49. Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R, et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncol. 2022; 8:e215445. PMID: 34792531.

50. Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022; 40:2546–2556. PMID: 35483010.

51. Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, et al. Preoperative treatment of locally advanced rectal cancer. N Engl J Med. 2023; 389:322–334. PMID: 37272534.

52. Basch E, Dueck AC, Mitchell SA, Mamon H, Weiser M, Saltz L, et al. Patient-reported outcomes during and after treatment for locally advanced rectal cancer in the PROSPECT Trial (Alliance N1048). J Clin Oncol. 2023; 41:3724–3734. PMID: 37270691.

53. Rahma OE, Yothers G, Hong TS, Russell MM, You YN, Parker W, et al. Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial. JAMA Oncol. 2021; 7:1225–1230. PMID: 34196693.

54. Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022; 386:2363–2376. PMID: 35660797.

55. Lee SH. Total neoadjuvant therapy for rectal cancer: evidence and challenge. Ann Coloproctol. 2023; 39:301–306. PMID: 37648423.

56. Sychev S, Ponomarenko A, Chernyshov S, Alekseev M, Mamedli Z, Kuzmichev D, et al. Total neoadjuvant therapy in rectal cancer: a network meta-analysis of randomized trials. Ann Coloproctol. 2023; 39:289–300. PMID: 37038270.

57. Zhang X, Ma S, Guo Y, Luo Y, Li L. Total neoadjuvant therapy versus standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis of 15 trials. PLoS One. 2022; 17:e0276599. PMID: 36331947.

58. Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, et al. Rectal cancer, version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20:1139–1167. PMID: 36240850.

59. Varela C, Kim NK. Surgical treatment of low-lying rectal cancer: updates. Ann Coloproctol. 2021; 37:395–424. PMID: 34961303.

60. Oh BY. Advances in surgery for locally advanced rectal cancer. Ann Coloproctol. 2022; 38:279–280. PMID: 36059073.

61. Ng JY, Chen CC. Transanal total mesorectal excision for rectal cancer: it’s come a long way and here to stay. Ann Coloproctol. 2022; 38:283–289. PMID: 36059075.

62. Piozzi GN, Kim SH. Robotic intersphincteric resection for low rectal cancer: technical controversies and a systematic review on the perioperative, oncological, and functional outcomes. Ann Coloproctol. 2021; 37:351–367. PMID: 34784706.

63. Yoo RN, Kye BH, Kim H, Kim G, Cho HM. The pattern of bowel dysfunction in patients with rectal cancer following the multimodal treatment: anorectal manometric measurements at before and after chemoradiation therapy, and postoperative 1 year. Ann Coloproctol. 2023; 39:32–40. PMID: 35279968.

64. Alessa M, Bae HW, Alawfi H, Sakr A, Sauri F, Kim NK. Neorectal mucosal prolapse after intersphincteric resection for low-lying rectal cancer: a case report. Ann Coloproctol. 2021; 37(Suppl 1):S15–S17. PMID: 33887818.

65. Wiltink LM, Marijnen CA, Meershoek-Klein Kroonenberg E, van de Velde CJ, Nout RA. A comprehensive longitudinal overview of health-related quality of life and symptoms after treatment for rectal cancer in the TME trial. Acta Oncol. 2016; 55:502–508. PMID: 26406287.

66. van der Heijden JA, van de Pas KG, van den Broek FJ, van Dielen FM, Slooter GD, Maaskant-Braat AJ. Oncological and functional outcomes of transanal total mesorectal excision in a teaching hospital in the Netherlands. Ann Coloproctol. 2022; 38:28–35. PMID: 34182715.

67. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004; 240:711–718. PMID: 15383798.

68. Beard BW, Rettig RL, Ryoo JJ, Parker RA, McLemore EC, Attaluri V. Watch-and-wait compared to operation for patients with complete response to neoadjuvant therapy for rectal cancer. J Am Coll Surg. 2020; 231:681–692. PMID: 33121903.

69. Dulskas A, Caushaj PF, Grigoravicius D, Zheng L, Fortunato R, Nunoo-Mensah JW, et al. International Society of University Colon and Rectal Surgeons survey of surgeons’ preference on rectal cancer treatment. Ann Coloproctol. 2023; 39:307–314. PMID: 36217808.

70. Park MY, Yu CS, Kim TW, Kim JH, Park JH, Lee JL, et al. Efficacy of preoperative chemoradiotherapy in patients with cT2N0 distal rectal cancer. Ann Coloproctol. 2023; 39:250–259. PMID: 35368177.

71. Son GM. Organ preservation for early rectal cancer using preoperative chemoradiotherapy. Ann Coloproctol. 2023; 39:191–192. PMID: 37415474.

72. Bach SP, Gilbert A, Brock K, Korsgen S, Geh I, Hill J, et al. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study. Lancet Gastroenterol Hepatol. 2021; 6:92–105. PMID: 33308452.

73. Kim CH. The risk-benefit trade-off in local excision of early rectal cancer. Ann Coloproctol. 2022; 38:95–96. PMID: 35436839.

74. Kang YM, Chao TF, Wang TH, Hu YW. Increased risk of pelvic fracture after radiotherapy in rectal cancer survivors: a propensity matched study. Cancer Med. 2019; 8:3639–3647. PMID: 31104362.

75. Park IJ. Precision medicine for primary rectal cancer will become a reality. Ann Coloproctol. 2022; 38:281–282. PMID: 36059074.

76. Joo JI, Lim SW, Oh BY. Prognostic impact of carcinoembryonic antigen levels in rectal cancer patients who had received neoadjuvant chemoradiotherapy. Ann Coloproctol. 2021; 37:179–185. PMID: 33971705.

77. Kang S. Carcinoembryonic antigen, the most accessible test for predicting colorectal cancer prognosis: exploring alternative roles. Ann Coloproctol. 2021; 37:129–130. PMID: 34233114.